rs4073259
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000617770.4(ALOX5AP):c.117-3417G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.497 in 152,190 control chromosomes in the GnomAD database, including 21,664 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.50 ( 21664 hom., cov: 33)
Consequence
ALOX5AP
ENST00000617770.4 intron
ENST00000617770.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.520
Publications
17 publications found
Genes affected
ALOX5AP (HGNC:436): (arachidonate 5-lipoxygenase activating protein) This gene encodes a protein which, with 5-lipoxygenase, is required for leukotriene synthesis. Leukotrienes are arachidonic acid metabolites which have been implicated in various types of inflammatory responses, including asthma, arthritis and psoriasis. This protein localizes to the plasma membrane. Inhibitors of its function impede translocation of 5-lipoxygenase from the cytoplasm to the cell membrane and inhibit 5-lipoxygenase activation. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2011]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.643 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ALOX5AP | NM_001204406.2 | c.117-3417G>A | intron_variant | Intron 1 of 5 | NP_001191335.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ALOX5AP | ENST00000617770.4 | c.117-3417G>A | intron_variant | Intron 1 of 5 | 1 | ENSP00000479870.1 |
Frequencies
GnomAD3 genomes AF: 0.497 AC: 75655AN: 152072Hom.: 21663 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
75655
AN:
152072
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.497 AC: 75678AN: 152190Hom.: 21664 Cov.: 33 AF XY: 0.497 AC XY: 37002AN XY: 74408 show subpopulations
GnomAD4 genome
AF:
AC:
75678
AN:
152190
Hom.:
Cov.:
33
AF XY:
AC XY:
37002
AN XY:
74408
show subpopulations
African (AFR)
AF:
AC:
8326
AN:
41530
American (AMR)
AF:
AC:
7469
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
AC:
2052
AN:
3472
East Asian (EAS)
AF:
AC:
2512
AN:
5168
South Asian (SAS)
AF:
AC:
2279
AN:
4830
European-Finnish (FIN)
AF:
AC:
7291
AN:
10590
Middle Eastern (MID)
AF:
AC:
151
AN:
294
European-Non Finnish (NFE)
AF:
AC:
44065
AN:
67986
Other (OTH)
AF:
AC:
1115
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
1756
3513
5269
7026
8782
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
658
1316
1974
2632
3290
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1457
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.